Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Ihle, Michaela A ^a   Fassunke, Jana ^a   König, Katharina ^a   Grünewald, Inga ^a,c   Schlaak, Max ^a   Kreuzberg, Nicole ^a   Tietze, Lothar ^b   Schildhaus, Hans Ulrich ^a,d   Büttner, Reinhard ^a   Merkelbach Bruse, Sabine ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Institute of Pathology   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

BRAF mutational analysis; Cobas BRAF V600 test; HRM; Immunohistochemistry; Next generation sequencing; Therascreen BRAF pyro kit

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; LEUCINE; VALINE; VEMURAFENIB;

AMINO ACID SUBSTITUTION; ANALYZER; ARTICLE; CANCER TISSUE; CODON; CONTROLLED STUDY; CROSS REACTION; DIAGNOSTIC EQUIPMENT; DNA EXTRACTION; EXON; GENE FREQUENCY; GENE TECHNOLOGY; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MEDICAL DEVICE; MELANOMA; MICRODISSECTION; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PYROSEQUENCING; ROBOTICS; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; SEQUENCER; SOMATIC MUTATION; SPECTROPHOTOMETER; TISSUE FIXATION;

ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; INDOLES; MELANOMA; MOLECULAR TARGETED THERAPY; MUTATION; PARAFFIN EMBEDDING; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84892377126     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-13     Document Type: Article

References (59)

1. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997, 9(2):180-186. 10.1016/S0955-0674(97)80061-0, 9069255.
2. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 2009, 23(3):529-545. ix, 10.1016/j.hoc.2009.04.001, 19464601.
3. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005, 12(2):245-262. 10.1677/erc.1.0978, 15947100.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954. 10.1038/nature00766, 12068308.
5. Wellcome Trust Sanger Institute Catalogue of somatic mutations in cancer (COSMIC) database http://www.sanger.ac.uk/genetics/CGP/cosmic, Wellcome Trust Sanger Institute.
6. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Briefings in Bioinformatics 2012, http://dx.doi.org/10.1093/bib/bbs017.
7. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010, 8:67. 10.1186/1479-5876-8-67, 2917408, 20630094.
8. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363(9):809-819. 10.1056/NEJMoa1002011, 3724529, 20818844.
9. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516. 10.1056/NEJMoa1103782, 3549296, 21639808.
10. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010, 23(2):190-200. 10.1111/j.1755-148X.2010.00685.x, 2848976, 20149136.
11. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010, 70(13):5518-5527. 10.1158/0008-5472.CAN-10-0646, 20551065.
12. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. The role of BRAF V600 mutation in melanoma. J Transl Med 2012, 10:85. 10.1186/1479-5876-10-85, 3391993, 22554099.
13. Fisher R, Larkin J. Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res 2012, 4:243-252. 3421463, 22904646.
14. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379(9829):1893-1901. 10.1016/S0140-6736(12)60398-5, 22608338.
15. Ponti G, Pellacani G, Tomasi A, Gelsomino F, Spallanzani A, Depenni R, Al Jalbout S, Simi L, Garagnani L, Borsari S, Conti A, Ruini C, Fontana A, Luppi G. The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. J Clin Pathol 2013, 66(5):441-445. 10.1136/jclinpath-2012-201345, 23463675.
16. Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer 2013, 49(5):1073-1079. 10.1016/j.ejca.2012.11.004, 23237741.
17. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367(18):1694-1703. 10.1056/NEJMoa1210093, 3549295, 23020132.
18. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116(6):855-867. 10.1016/S0092-8674(04)00215-6, 15035987.
19. Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Janne PA, Johnson BE, Chin L, Wong KK. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007, 67(10):4933-4939. 10.1158/0008-5472.CAN-06-4592, 17510423.
20. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007, 21(4):379-384. 10.1101/gad.1516407, 1804325, 17299132.
21. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011, 29(15):2046-2051. 10.1200/JCO.2010.33.1280, 3107760, 21483012.
22. Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013, 31(8):1097-1104. 10.1200/JCO.2012.42.9829, 23401445.
23. Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med 2012, 4(136):136ra-170.
24. Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Cote JF, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile JF. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013, 15(1):94-100. 10.1016/j.jmoldx.2012.09.001, 23159108.
25. Tol J, Dijkstra JR, Vink-Borger ME, Nagtegaal ID, Punt CJ, Van Krieken JH, Ligtenberg MJ. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2010, 14(8):2122-2131.
26. Eckhart L, Bach J, Ban J, Tschachler E. Melanin binds reversibly to thermostable DNA polymerase and inhibits its activity. Biochem Biophys Res Commun 2000, 271(3):726-730. 10.1006/bbrc.2000.2716, 10814530.
27. Carbonell P, Turpin MC, Torres-Moreno D, Molina-Martinez I, Garcia-Solano J, Perez-Guillermo M, Conesa-Zamora P. Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E. J Mol Diagn 2011, 13(5):467-473. 10.1016/j.jmoldx.2011.03.009, 3157612, 21708284.
28. Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009, 133(10):1600-1606.
29. Ney JT, Froehner S, Roesler A, Buettner R, Merkelbach-Bruse S. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS, BRAF, PIK3CA, and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. Arch Pathol Lab Med 2012, 136(9):983-992. 10.5858/arpa.2011-0176-OA, 22938585.
30. Balic M, Pichler M, Strutz J, Heitzer E, Ausch C, Samonigg H, Cote RJ, Dandachi N. High quality assessment of DNA methylation in archival tissues from colorectal cancer patients using quantitative high-resolution melting analysis. J Mol Diagn 2009, 11(2):102-108. 10.2353/jmoldx.2009.080109, 2665859, 19179456.
31. Do H, Dobrovic A. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget 2012, 3(5):546-558. 3388184, 22643842.
32. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006, 354(5):526-528. author reply 526-528.
33. Lade-Keller J, Romer KM, Guldberg P, Riber-Hansen R, Hansen LL, Steiniche T, Hager H, Kristensen LS. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn 2013, 15(1):70-80. 10.1016/j.jmoldx.2012.08.003, 23159593.
34. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, Murphy KM. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010, 12(4):425-432. 10.2353/jmoldx.2010.090188, 2893626, 20431034.
35. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012, 366(3):207-215. 10.1056/NEJMoa1105358, 3724537, 22256804.
36. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012, 30(3):316-321. 10.1200/JCO.2011.36.7680, 3269955, 22067401.
37. Gong M, Foo SH, Lin L, Liu ET, Gharizadeh B, Goel S. Pyrosequencing enhancement for better detection limit and sequencing homopolymers. Biochem Biophys Res Commun 2010, 401(1):117-123. 10.1016/j.bbrc.2010.09.022, 20833128.
38. Shen S, Qin D. Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis. Diagn Pathol 2012, 7:56. 10.1186/1746-1596-7-56, 3433338, 22640803.
39. Chen G, Olson MT, O'Neill A, Norris A, Beierl K, Harada S, Debeljak M, Rivera-Roman K, Finley S, Stafford A, Gocke CD, Lin MT, Eshleman JR. A virtual pyrogram generator to resolve complex pyrosequencing results. J Mol Diagn 2012, 14(2):149-159. 10.1016/j.jmoldx.2011.12.001, 3349844, 22316529.
40. Skorokhod A, Helmbold P, Brors B, Schirmacher P, Enk A, Penzel R. Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600.). PLoS One 2013, 8(3):e59221. 10.1371/journal.pone.0059221, 3608589, 23555633.
41. Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A, Letrero R, Herlyn M, Edwards RH. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 2007, 9(4):464-471. 10.2353/jmoldx.2007.060191, 1975103, 17690212.
42. Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Vaks J, Langland R, Lawrence HJ, de Castro DG. Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib. PLoS One 2013, 8(1):e53733. 10.1371/journal.pone.0053733, 3542342, 23326492.
43. Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG. Molecular platforms utilized to detect BRAF V600E mutation in melanoma. Semin Cutan Med Surg 2012, 31(4):267-273. 10.1016/j.sder.2012.07.007, 23174497.
44. Anderson S, Bloom KJ, Vallera DU, Rueschoff J, Meldrum C, Schilling R, Kovach B, Lee JR, Ochoa P, Langland R, Halait H, Lawrence HJ, Dugan MC. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012, 136(11):1385-1391. 10.5858/arpa.2011-0505-OA, 22332713.
45. Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, Hillman G, Wu L, Lawrence HJ. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diag Mol Path 2012, 21(1):1-8.
46. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366(8):707-714. 10.1056/NEJMoa1112302, 3724515, 22356324.
47. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: new insights and new therapies. J Invest Dermatol 2012, 132(3 Pt 2):854-863. 3759013, 22217739.
48. Dong Q, Dougan DR, Gong X, Halkowycz P, Jin B, Kanouni T, O'Connell SM, Scorah N, Shi L, Wallace MB, Zhou F. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg Med Chem Lett 2011, 21(5):1315-1319. 10.1016/j.bmcl.2011.01.071, 21310613.
49. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012, 2(9):791-797. 10.1158/2159-8290.CD-12-0097, 3449158, 22798288.
50. da Rocha DS, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH, Giuliani R, Pignatti F. The European Medicines Agency review of vemurafenib (Zelboraf(R)) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2013, 49(7):1654-1661. 10.1016/j.ejca.2013.01.015, 23481513.
51. Rechsteiner M, von Teichman A, Ruschoff JH, Fankhauser N, Pestalozzi B, Schraml P, Weber A, Wild P, Zimmermann D, Moch H. KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics. J Mol Diagn 2013, 15(3):299-311. 10.1016/j.jmoldx.2013.02.001, 23531339.
52. Ross JS, Cronin M. Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol 2011, 136(4):527-539. 10.1309/AJCPR1SVT1VHUGXW, 21917674.
53. Capper D, Berghoff AS, Magerle M, Ilhan A, Wohrer A, Hackl M, Pichler J, Pusch S, Meyer J, Habel A, Petzelbauer P, Birner P, von Deimling A, Preusser M. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012, 123(2):223-233. 10.1007/s00401-011-0887-y, 22012135.
54. Skorokhod A, Capper D, von Deimling A, Enk A, Helmbold P. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 2012, 67(3):488-491. 10.1016/j.jaad.2012.03.022, 22890732.
55. Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol 2013, 37(3):413-420. 10.1097/PAS.0b013e318271249e, 23211290.
56. Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013, 37(1):61-65. 10.1097/PAS.0b013e31826485c0, 23026937.
57. Heinzerling L, Kuhnapfel S, Meckbach D, Baiter M, Kaempgen E, Keikavoussi P, Schuler G, Agaimy A, Bauer J, Hartmann A, Kiesewetter F, Schneider-Stock R. Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice. Br J Cancer 2013, 108(10):2164-2171. 10.1038/bjc.2013.143, 23579220.
58. Reed GH, Kent JO, Wittwer CT. High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 2007, 8(6):597-608. 10.2217/14622416.8.6.597, 17559349.
59. Jancik S, Drabek J, Berkovcova J, Xu YZ, Stankova M, Klein J, Kolek V, Skarda J, Tichy T, Grygarkova I, Radzioch D, Hajduch M. A comparison of direct sequencing, pyrosequencing, high resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas. J Exp Clin Cancer Res 2012, 31:79. 10.1186/1756-9966-31-79, 3542008, 22995035.